Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
Cash to Debt No Debt
TTHI's Cash to Debt is ranked higher than
86% of the 919 Companies
in the Global Biotechnology industry.

( Industry Median: 16.62 vs. TTHI: No Debt )
TTHI' s 10-Year Cash to Debt Range
Min: 4.13   Max: No Debt
Current: No Debt

F-Score: 3
Z-Score: 14.63
M-Score: -3.59
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
Operating margin (%) -178.28
TTHI's Operating margin (%) is ranked higher than
65% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. TTHI: -178.28 )
TTHI' s 10-Year Operating margin (%) Range
Min: -13750.46   Max: -5.76
Current: -178.28

-13750.46
-5.76
Net-margin (%) -150.42
TTHI's Net-margin (%) is ranked higher than
66% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -69.75 vs. TTHI: -150.42 )
TTHI' s 10-Year Net-margin (%) Range
Min: -13048.62   Max: 0.13
Current: -150.42

-13048.62
0.13
ROE (%) -26.10
TTHI's ROE (%) is ranked higher than
73% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -28.10 vs. TTHI: -26.10 )
TTHI' s 10-Year ROE (%) Range
Min: -66.78   Max: 0.07
Current: -26.1

-66.78
0.07
ROA (%) -23.13
TTHI's ROA (%) is ranked higher than
72% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -21.69 vs. TTHI: -23.13 )
TTHI' s 10-Year ROA (%) Range
Min: -55.68   Max: 0.06
Current: -23.13

-55.68
0.06
ROC (Joel Greenblatt) (%) -7794.84
TTHI's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -217.20 vs. TTHI: -7794.84 )
TTHI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4133.77   Max: -539.43
Current: -7794.84

-4133.77
-539.43
Revenue Growth (%) 52.20
TTHI's Revenue Growth (%) is ranked higher than
97% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. TTHI: 52.20 )
TTHI' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 91.3
Current: 52.2

0
91.3
EPS Growth (%) -100.00
TTHI's EPS Growth (%) is ranked higher than
52% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. TTHI: -100.00 )
TTHI' s 10-Year EPS Growth (%) Range
Min: -100   Max: 51.8
Current: -100

-100
51.8
» TTHI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

TTHI Guru Trades in Q3 2013

Jim Simons 72,400 sh (+135.83%)
» More
Q4 2013

TTHI Guru Trades in Q4 2013

Jim Simons 119,800 sh (+65.47%)
» More
Q1 2014

TTHI Guru Trades in Q1 2014

Jim Simons 131,100 sh (+9.43%)
» More
Q2 2014

TTHI Guru Trades in Q2 2014

Jim Simons 131,300 sh (+0.15%)
» More
» Details

Insider Trades

Latest Guru Trades with TTHI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 4.64
TTHI's P/B is ranked higher than
76% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 5.71 vs. TTHI: 4.64 )
TTHI' s 10-Year P/B Range
Min: 0.63   Max: 9.43
Current: 4.64

0.63
9.43
PFCF 385.00
TTHI's PFCF is ranked higher than
88% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. TTHI: 385.00 )
TTHI' s 10-Year PFCF Range
Min: 9.78   Max: 27.38
Current: 385

9.78
27.38
EV-to-EBIT -13.61
TTHI's EV-to-EBIT is ranked higher than
81% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. TTHI: -13.61 )
TTHI' s 10-Year EV-to-EBIT Range
Min: 0.5   Max: 7.6
Current: -13.61

0.5
7.6
Current Ratio 12.54
TTHI's Current Ratio is ranked higher than
92% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 3.97 vs. TTHI: 12.54 )
TTHI' s 10-Year Current Ratio Range
Min: 2.24   Max: 30.83
Current: 12.54

2.24
30.83
Quick Ratio 12.54
TTHI's Quick Ratio is ranked higher than
92% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 3.81 vs. TTHI: 12.54 )
TTHI' s 10-Year Quick Ratio Range
Min: 1.66   Max: 30.83
Current: 12.54

1.66
30.83

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.54
TTHI's Price/Net Cash is ranked higher than
91% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 86.53 vs. TTHI: 5.54 )
TTHI' s 10-Year Price/Net Cash Range
Min: 2.13   Max: 64
Current: 5.54

2.13
64
Price/Net Current Asset Value 5.50
TTHI's Price/Net Current Asset Value is ranked higher than
90% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 52.38 vs. TTHI: 5.50 )
TTHI' s 10-Year Price/Net Current Asset Value Range
Min: 1.7   Max: 53.33
Current: 5.5

1.7
53.33
Price/Tangible Book 5.46
TTHI's Price/Tangible Book is ranked higher than
80% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 9.10 vs. TTHI: 5.46 )
TTHI' s 10-Year Price/Tangible Book Range
Min: 1.52   Max: 38.25
Current: 5.46

1.52
38.25
Forward Rate of Return (Yacktman) -5.04
TTHI's Forward Rate of Return (Yacktman) is ranked higher than
79% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: -10.76 vs. TTHI: -5.04 )
TTHI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -40.6   Max: -9.4
Current: -5.04

-40.6
-9.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:TTH.Canada, RFYA.Germany
Transition Therapeutics Inc. was incorporated pursuant to the Business Corporations Act (Ontario) on July 6, 1998 as 'Transition Therapeutics and Diagnostics Inc.' The Corporation filed articles of amendment on October 12, 2000 and on October 19, 2000 to create a class of non-voting shares (the 'Class B Shares') and to amend certain attributes of its Common Shares. On November 2, 2000, the Corporation filed articles of amendment to delete its private company restrictions. On December 14, 2000, the Corporation filed articles of amendment to change its name to 'Transition Therapeutics Inc.' The Company is a product-focused biopharmaceutical company developing novel therapeutics for disease indications with markets. The Corporation considers itself to be in one business segment; that is the research and development of therapeutic agents. Its strategic focus is on building shareholder value. To effectively achieve this, the Corporation has established a business model based on the following steps: 1) identifying attractive early stage technologies targeting main markets; 2) moving these products through the clinic to provide validation; 3) considering additional product opportunities; 4) identifying partners with the infrastructure and resources to complete late stage clinical development and product commercialization; and 5) identifying new product opportunities to replenish the Corporation's product pipeline. Its technologies in development are as follows: (i) ELND005 (AZD-103) for the treatment of Alzheimer's disease; (ii) TT-301 and TT-302 which may have a therapeutic effect on diseases including arthritis, Alzheimer's disease, traumatic brain injury, intracerebral haemorrhage, and others, and (iii) TT401/402 for the treatment of diabetes. The Corporation relies on third party manufacturers to supply all of its drug substances and the finished dosage form for its preclinical and clinical products. On July 15, 2011, Transition announced that ELND005 Phase 2 clinical trial data would be presented at the International Conference of Alzheimer's Disease (ICAD) meeting on July 18, 2011. Elan and Transition intend to share further detail regarding the Phase 2 data in a peer-reviewed publication.
» More Articles for NAS:TTHI

Headlines

Articles On GuruFocus.com
Hardest Hit Companies of the Day: Transition Therapeutics Inc., Sunesis Pharmaceuticals Inc., GenCor Dec 15 2009 

More From Other Websites
Transition Therapeutics to Hold Conference Call on Full Year Fiscal 2014 Financial Results on... Sep 22 2014
Transition Therapeutics to Hold Conference Call on Full Year Fiscal 2014 Financial Results on... Sep 22 2014
Transition Therapeutics to Present at the 16th Annual Rodman & Renshaw Global Investment Conference Sep 05 2014
Transition Therapeutics to Present at the 16th Annual Rodman & Renshaw Global Investment Conference Sep 05 2014
UPDATE: H.C. Wainwright & Co. Initiates Coverage On Epizyme, Transition Therapeutics Jul 15 2014
Coverage initiated on Transition Therapeutics by H.C. Wainwright Jul 15 2014
Transition Therapeutics Appoints Carl Damiani as Chief Operating Officer Jul 11 2014
Transition Therapeutics Appoints Carl Damiani as Chief Operating Officer Jul 11 2014
Transition Therapeutics (TTHI) is in Overbought Territory: What's Next? Jun 25 2014
Transition Therapeutics: 5 Different Insiders Have Purchased Shares This Month Jun 24 2014
Transition Therapeutics Announces Closing of Private Placement Equity Financing Jun 23 2014
Transition Therapeutics Announces Closing of Private Placement Equity Financing Jun 23 2014
Transition Therapeutics Enters Into a Private Placement with Investors to Receive up to US$30.8... Jun 06 2014
Transition Therapeutics Enters Into a Private Placement with Investors to Receive up to US$30.8... Jun 06 2014
Transition Therapeutics to host investor meeting May 27 2014
Transition Therapeutics to Host Investor Day and Webcast on May 28th in New York City May 27 2014
Transition Therapeutics to Host Investor Day and Webcast on May 28th in New York City May 27 2014
Transition Therapeutics to Present at Jefferies 2014 Global Healthcare Conference May 22 2014
Transition Therapeutics to Present at Jefferies 2014 Global Healthcare Conference May 22 2014
Transition Therapeutics begins Phase 2 study of diabetes candidate TT-401 May 15 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK